Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Authors
Keywords
-
Journal
CANCER
Volume 121, Issue 23, Pages 4158-4164
Publisher
Wiley
Online
2015-08-27
DOI
10.1002/cncr.29646
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Acute Lymphoblastic Leukemia
- (2017) Joseph C. Alvarnas et al. Journal of the National Comprehensive Cancer Network
- Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy
- (2013) F. Ravandi et al. BLOOD
- UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia
- (2013) A. K. Fielding et al. BLOOD
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- (2013) J.E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A GRAALL Study
- (2012) Aline Tanguy-Schmidt et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
- (2012) H. Kantarjian et al. BLOOD
- Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia
- (2012) H Pfeifer et al. LEUKEMIA
- Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
- (2012) Jorge E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2011) N. Boulos et al. BLOOD
- Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2011) R. Foa et al. BLOOD
- Current Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- (2011) A. K. Fielding Hematology-American Society of Hematology Education Program
- Philadelphia-Positive Acute Lymphoblastic Leukemia—Is Bone Marrow Transplant Still Necessary?
- (2010) Adele K. Fielding BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia
- (2010) F. Ravandi et al. BLOOD
- Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
- (2009) R. Bassan et al. BLOOD
- Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
- (2009) Kirk R. Schultz et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started